Key result
Low-dose vasopressin lacks reported quantitative data for maintaining arterial pressure in severe heart failure.
Why the study?
PDE III inhibitors induce vasodilation and hypotension in patients with severe heart failure, and a specific antagonist for this vascular action could be clinically useful.
Does low-dose vasopressin maintain arterial pressure in patients with severe congestive heart failure receiving PDE III inhibitors?
Does low-dose vasopressin maintain arterial pressure in patients with severe congestive heart failure receiving PDE III inhibitors?
The study investigates whether low-dose vasopressin can maintain arterial pressure in severe heart failure patients experiencing PDE III inhibitor-induced hypotension.
Answers are grounded in this paper and cite their sources.
No quantitative results available to inform vasopressin use; leaves open prospective evaluation in severe HF with PDE III inhibitor hypotension.
Management of patients with severe heart failure and hemodynamic instability remains a difficult challenge. Phosphodiesterase (PDE) III inhibitors increase myocardial contractility and potentiate the inotropy of β agonists, and can be very useful in this setting. 1 Colucci W.S Denniss A.R Quigg R.J Ludmer P.L Marsh J.D Gauthier D.F Leather man GFIntracoronary infusion of dobutamine to patients with and without severe congestive heart failure. J Clin Invest. 1988; 81: 1103-1110 Crossref PubMed Scopus (114) Google Scholar , 2 Uretsky B.F Lawless C.E Verbalis J.G Valdes A.M Kolesar J.A Reddy P.S Combined therapy with dobutamine and amrinone in severe heart failure. Chest. 1987; 92: 657-662 Abstract Full Text Full Text PDF PubMed Google Scholar , 3 Kauffman R.F Schenck K.W Utterback B.G Crowe V.G Cohen M.L In vitro vascular relaxation by new inotropic agents relationship to phosphodiesterase inhibition and cyclic nucleotides. J Pharmacol Exp Ther. 1987; 242: 864-872 PubMed Google Scholar However, PDE III inhibitors also act in vascular smooth muscle to increase cyclic adenosine monophosphate and, via PDE IV inhibition, cyclic guanosine monophosphate. 3 Kauffman R.F Schenck K.W Utterback B.G Crowe V.G Cohen M.L In vitro vascular relaxation by new inotropic agents relationship to phosphodiesterase inhibition and cyclic nucleotides. J Pharmacol Exp Ther. 1987; 242: 864-872 PubMed Google Scholar , 4 Lugnier C Komas N Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP role in vasodilatation. Eur Heart J. 1993; 14: 141-148 Crossref PubMed Scopus (2) Google Scholar Although there is little response to these changes in normal subjects, 5 DeGuzman N.T Munoz O Pamer R.F Davolos D Alousi A Clinical evaluation of amrinone (A)—new inotropic agent. Circulation. 1978; 58: 19 Google Scholar in patients with severe heart failure and neurohumoral activation of adenylate and guanylate cyclases, 6 Zheng X Ma S.J Zhang T.H Chen S.C Plasma levels of cyclic nucleotides in congestive heart failure and their clinical implication. Int J Cardiol. 1993; 40: 7-15 Abstract Full Text PDF PubMed Scopus (6) Google Scholar PDE III inhibitors induce vasodilation and hypotension. 7 Ferry D.R Kennedy G.T Rourke R.A Crawford M.H Hemodynamic effects of prolonged intravenous therapy with enoximone in patients with severe congestive heart failure. J Cardiovasc Pharmacol. 1988; 11: 115-122 Crossref PubMed Scopus (13) Google Scholar , 8 Taylor S.H Verma S.P Hussain M Reynolds G Jackson N.C Hafizullah M Richmond A Silke B Intravenous amrinone in left ventricular failure complicated by acute myocardial infarction. Am J Cardiol. 1985; 56: 29B-32B Abstract Full Text PDF PubMed Scopus (30) Google Scholar A specific antagonist for the vascular action of PDE inhibitors could be clinically useful, and exogenous arginine vasopressin was of interest because this hormone inhibits activation of both adenylate cyclase and guanylate cyclase in vascular smooth muscle. 9 Nambi P, Whitman M, Gessner G, Aiyar N, Crooke ST. Vasopressin-mediated inhibition of atrial natriuretic factor-stimulated cGMP accumulation in an established smooth muscle cell line. Proc Natl Acad Sci USA 1986;83:8492–1895. Google Scholar , 10 Nambi P Whitman M Stassen F.L Crooke S.T Vascular vasopressin receptors mediate inhibition of beta adrenergic receptor-induced cyclic AMP accumulation. J Pharmacol Exp Ther. 1986; 237: 143-146 PubMed Google Scholar Accordingly, we examined whether vasopressin at low doses, having no pressor effect in normal subjects, could maintain arterial pressure in patients with severe congestive heart failure receiving PDE III inhibitors.
No takes yet. Share an insight, caveat, or question.
Gold et al. (2000) studied Severe congestive heart failure with milrinone-induced hypotension. Vasopressin was evaluated on Maintenance of arterial pressure. The efficacy of low-dose vasopressin for maintaining arterial pressure in severe heart failure was examined, but no quantitative results are reported in the abstract.
Synapse has enriched 10 related papers. Consider them for comparative context: